Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEK162 in Noonan Syndrome Hypertrophic Cardiomyopathy
NCT01556568Phase 2Withdrawn
- Sponsor
- Pfizer
- Start
- Feb 2012
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of binimetinib in Noonan syndrome, sponsored by Pfizer. Planned start Feb 2012; status: withdrawn.
02
Drugs
binimetinib
03
Conditions
Noonan syndrome
Beyond the preview
Go deeper on NCT01556568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01556568.